Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: A case-control study

Arthritis Research and Therapy

Volumn 13, Issue 2, 2011, Pages

  Overbeek, Maria J ^a   Boonstra, Anco ^a   Voskuyl, Alexandre E ^a   Vonk, Madelon C ^b   Vonk Noordegraaf, Anton ^a   van Berkel, Maria P A ^a   Mooi, Wolter J ^a   Dijkmans, Ben A C ^a   Hondema, Laurens S ^a   Smit, Egbert F ^a   Grünberg, Katrien ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHODIESTERASE V INHIBITOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROSTACYCLIN; BIOLOGICAL MARKER; EGFR PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LUNG BLOOD VESSEL; MALE; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; SYSTEMIC SCLEROSIS; AGED; BIOSYNTHESIS; CASE CONTROL STUDY; IMMUNOHISTOCHEMISTRY; LUNG; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY ARTERY; PULMONARY VEIN; VASCULARIZATION;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MIDDLE AGED; PULMONARY ARTERY; PULMONARY VEINS; PULMONARY VENO-OCCLUSIVE DISEASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SCLERODERMA, SYSTEMIC;

EID: 79953852372     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3315     Document Type: Article

References (51)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003. 10.1056/NEJMra0806188, 19420368.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944. 10.1136/ard.2006.066068, 1955114, 17329309.
3. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, Kahan A, Cabane J, Francès C, Launay D, Mouthon L, Allanore Y, Tiev KP, Clerson P, De Groote P, Humbert M. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005, 52:3792-3800. 10.1002/art.21433, 16320330.
4. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62:1088-1093. 10.1136/ard.62.11.1088, 1754353, 14583573.
5. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, Torpy C, Goldsmith K, Hodgkins D, Hughes RJ, Pepke-Zaba J, Coghlan JG. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179:151-157.
6. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, Krishnan JA, Wighley F, Hassoun PM. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006, 54:3043-3050. 10.1002/art.22069, 16947776.
7. Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, Launay D, Mouthon L, Jego P, Cabane J, De Groote P, Chabrol A, Lazareth I, Guillevin L, Clerson P, Humbert M, . ItinérAIR-Sclérodermie Study Investigators Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology (Oxford) 2009, 48:304-308. 2644045, 19174571, ItinérAIR-Sclérodermie Study Investigators.
8. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344-350. 10.1378/chest.123.2.344, 12576350.
9. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005, 24:1626-1631. 10.1016/j.healun.2004.12.113, 16210140.
10. Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007, 29:469-475. 10.1183/09031936.00081706, 17079256.
11. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulodo T, Frost A, Roux S, Leconte I, Landzberg M, Simmoneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903. 10.1056/NEJMoa012212, 11907289.
12. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliot CG, Hill NS, Langleben D, Schilz RJ, Mc Laughlin VV, Robins IM, Groves BM, Shapirp S, Medsger T. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425-434.
13. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Simmonneau G. Sildenafil for Pulmonary Arterial Hypertension Associated with Connective Tissue Disease. J Rheumatol 2007, 34:2417-2422.
14. Overbeek MJ, Lankhaar JW, Westerhof N, Voskuyl AE, Boonstra A, Bronzwaer JG, Marques KM, Smit EF, Dijkmans BA, Vonk-Noordegraaf A. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008, 31:1160-1166. 10.1183/09031936.00135407, 18216049.
15. Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516-522. 10.1002/art.10775, 12571862.
16. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003, 41:1028-1035. 10.1016/S0735-1097(02)02964-9, 12651053.
17. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, Krishnan JA, Wighley F, Hassoun PM. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006, 54:3043-3050. 10.1002/art.22069, 16947776.
18. Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516-522. 10.1002/art.10775, 12571862.
19. Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, Capron F. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007, 38:893-902. 10.1016/j.humpath.2006.11.022, 17376507.
20. Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk-Noordegraaf A, Smit EF, Dijkmans BA, Postmus PE, Mooi WJ, Heijdra Y, Grunberg K. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009, 34:371-379. 10.1183/09031936.00106008, 19282344.
21. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schet G, Gay S, Distler O. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56:311-322. 10.1002/art.22314, 17195235.
22. Gay S, Jones RE, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989, 92:301-303. 10.1111/1523-1747.ep12276895, 2918236.
23. Klareskog L, Gustafsson R, Scheynius A, Hallgren R. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990, 33:1534-1541. 10.1002/art.1780331011, 2171541.
24. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995, 22:1876-1883.
25. Pandolfi A, Florita M, Altomare G, Pigatto P, Donati MB, Poggi A. Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis. Proc Soc Exp Biol Med 1989, 191:1-4.
26. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009, 60:219-224. 10.1002/art.24186, 19116940.
27. Kawamoto T, Nishi M, Takahashi K, Nishiyama T, Sato JD, Taniguchi S. Stimulation by transforming growth factor-beta of epidermal growth factor-dependent growth of aged human fibro-blasts: recovery of high affinity EGE receptors and growth stimulation by EGF. In Vitro Cell Dev Biol 1989, 25:965-970. 10.1007/BF02624011, 2808227.
28. Tokiyama K, Yokota E, Niho Y. Epidermal growth factor receptor of fibroblasts from patients with scleroderma 1. J Rheumatol 1990, 17:1463-1468.
29. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005, 112:423-431. 10.1161/CIRCULATIONAHA.105.540542, 16027270.
30. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissman N, Seeger W, Grimmiger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821. 10.1172/JCI24838, 1236676, 16200212.
31. Dahal BK, Cornitescu T, Tretyn A, Pullamsetti SS, Kosanovic D, Dumitrascu R, Ghofrani HA, Weissmann N, Grimmiger F, Seeger W, Schermuly RT. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 2010, 181:158-167. 10.1164/rccm.200811-1682OC, 19850946.
32. Graves LM, Han J, Earp HS. Transactivation of the EGF receptor: is the PDGF receptor an unexpected accomplice?. Mol Interv 2002, 2:208-212. 10.1124/mi.2.4.208, 14993390.
33. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, Herve P, Emilie D, Eddahibi S, Simmonneau G, Souza R, Humbert M. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008, 178:81-88. 10.1164/rccm.200707-1037OC, 18420966.
34. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353:1412-1413. 10.1056/NEJMc051946, 16192491.
35. Overbeek MJ, Nieuw Amerongen GP, Boonstra A, Smit EF, Vonk-Noordegraaf A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 2008, 32:232-235. 10.1183/09031936.00054407, 18591341.
36. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006, 145:152-153.
37. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006, 61:736. 2104679, 16877696.
38. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088.
39. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
40. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004, 43:25S-32S. 10.1016/j.jacc.2004.02.033, 15194175.
41. Wagenvoort CA, Wagenvoort N. The pathology of pulmonary veno-occlusive disease. Virchows Arch A Pathol Anat Histol 1974, 364:69-79. 10.1007/BF01230858, 4217029.
42. Lantuejoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006, 30:850-857. 10.1097/01.pas.0000209834.69972.e5, 16819327.
43. Assaad AM, Kawut SM, Arcasoy SM, Rosenzweig EB, Wilt JS, Sonett JR, Borczuk AC. Platelet-derived growth factor is increased in pulmonary capillary hemangiomatosis. Chest 2007, 131:850-855. 10.1378/chest.06-1680, 17356103.
44. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Awedimento EV, Gabrielli A. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676. 10.1056/NEJMoa052955, 16790699.
45. Chi SS, Vetiska SM, Gill RS, Hsiung MS, Liu F, Van Tol HH. Transactivation of PDGFRbeta by dopamine D4 receptor does not require PDGFRbeta dimerization. Mol Brain 2010, 3:22. 10.1186/1756-6606-3-22, 2919524, 20659339.
46. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316. 524221, 15520863.
47. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 2005, 19:1-11. 10.1096/fj.04-2370com, 15629889.
48. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567. 10.1172/JCI31139, 1804347, 17332883.
49. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM, Voelkel NF. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001, 195:367-374. 10.1002/path.953, 11673836.
50. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005, 46:31-36. 10.1111/j.1365-2559.2005.02045.x, 15656883.
51. Tanaka H, Yamamoto M, Hashimoto N, Miyakoshi M, Tamakawa S, Yoshie M, Tokusashi Y, Yokoyama K, Yaginuma Y, Ogawa K. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. Cancer Res 2006, 66:11263-11270. 10.1158/0008-5472.CAN-06-1699, 17145871.